• Takeda 205

    To assess the safety and effectiveness of treatment with daily oral administration of dexlansoprazole 30 or 60 mg for 8 to 12 weeks in pediatric subjects aged 1 to 11 years, inclusive, with Erosive Esophagitis.

  • Takeda 204

    To assess the safety and effectiveness of treatment with daily oral administration of dexlansoprazole delayed release capsules (15,30, and 60 mg) in pediatric subjects aged 1 to 11 years with symptomatic nonerosive GERD.